MedTrace Logo

Laminar Airflow in Severe Asthma for Exacerbation Reduction

NCT03058497 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2017-02-23

No results posted yet for this study

Summary

To ascertain whether home-based nocturnal TLA usage over a 12 month period can reduce exacerbations and improve asthma control and quality of life as compared to placebo, whilst being cost-effective and acceptable to adults with poorly-controlled, severe allergic asthma.

Conditions

Interventions

DEVICE

Temperature-Controlled Laminar Airflow Device (Airsonett®)

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Portsmouth Hospitals NHS Trust

    lead OTHER_GOV

Principal Investigators

  • Anoop[ Chauhan · Portsmouth Hospitals NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03058497 on ClinicalTrials.gov